Trump announces trade deal with EU following months of negotiations
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) has received approval from the Nasdaq Hearings Panel to maintain its listing on the Nasdaq Capital Market, the biotech company announced Tuesday. According to InvestingPro data, the micro-cap company, currently valued at $3.63 million, has seen its stock decline nearly 100% year-to-date amid significant price volatility.
The panel’s decision follows a hearing held on June 26, where Polyrizon presented its plan to address concerns raised by Nasdaq’s Listing Qualifications Department. The department had issued a public interest determination under Listing Rule 5101 on May 23, citing the company’s private placement of securities dated March 31.
As part of the continued listing agreement, Polyrizon must regain compliance with the Minimum Bid Price Rule by October 17.
"We appreciate Nasdaq’s thoughtful consideration of this matter and are pleased to maintain our listing," said Tomer Izraeli, CEO of Polyrizon. He noted that following the private placement, the company has a cash balance of approximately $15.68 million. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 10.16, though it currently carries a weak overall financial health score.
The private placement involved the issuance of 5,962,073 ordinary shares, including 5,829,389 shares issued upon the exercise of warrants on an alternate cashless basis. All warrants issued in the transaction have now been exercised.
Polyrizon is implementing a formal internal control framework to govern future securities issuances and ensure compliance with Nasdaq listing standards, according to the company’s statement.
The development stage biotech company specializes in creating innovative intranasal hydrogels, focusing on technology that forms barrier protection in the nasal cavity against viruses and allergens. InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics to better evaluate early-stage biotech companies like Polyrizon.
The share amounts reflect a 1-for-250 reverse share split that the company implemented on May 27, according to the press release.
In other recent news, Polyrizon Ltd. announced promising preclinical results for its Trap & Target platform, an intranasal drug delivery system. The study demonstrated over 60% targeted deposition in favorable nasal cavity regions, potentially benefiting treatments for conditions like opioid overdose and epileptic seizures. Additionally, Polyrizon has initiated preclinical studies for intranasal Benzodiazepines delivery to treat acute seizures, leveraging its proprietary hydrogel technology. The company also reported a successful preliminary safety study for its PL-14 Allergy Blocker, which showed strong local tolerability in human nasal tissue models.
In corporate governance developments, board member Omer Srugo resigned, and the board confirmed the independence of four members. However, Polyrizon faces potential Nasdaq delisting due to shareholder dilution concerns, arising from securities issuance under a purchase agreement. The company plans to appeal the delisting decision, which currently does not affect its Nasdaq trading status. These developments reflect Polyrizon’s ongoing efforts in advancing its intranasal treatment solutions and addressing regulatory challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.